Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN022 in advanced solid tumors
NCT07292402Phase 1Recruiting
- Sponsor
- Alphamab Oncology
- Start
- Oct 2025
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of JSKN022 in Advanced Malignant Solid Neoplasm (AMSN) (11 arms), sponsored by Alphamab Oncology. Primary endpoints: Treatment-Emergent Adverse Events, Dose-Limiting Toxicity at 21 days and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
JSKN022
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT07292402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292402.